PacBio Grants Equity Incentive Award to New Employee
PacBio (NASDAQ: PACB) announced on January 14, 2022, that its Compensation Committee granted non-qualified stock options for 80,000 shares and restricted stock units (RSUs) for 40,000 shares to a new employee. This action is part of the 2020 Inducement Equity Incentive Plan, aimed at attracting talent. The options have an exercise price of $16.58, equal to the stock's closing price on January 10, 2022. Vesting for options and RSUs will occur over four years, aligning employee incentives with long-term company performance.
- Issuance of stock options and RSUs may strengthen employee retention and attract talent.
- The exercise price aligns with the market price, indicating no immediate dilution for shareholders.
- The granting of options and RSUs could lead to future dilution of shares if exercised.
MENLO PARK, Calif., Jan. 14, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 80,000 shares of PacBio common stock, and restricted stock units (“RSUs”) covering 40,000 shares of PacBio common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”) effective on January 10, 2022.
The 2020 Inducement Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of PacBio as an inducement material to such individual’s entering into employment with PacBio in accordance with Nasdaq Marketplace Rule 5635(c)(4).
The options have an exercise price of
About PacBio
Pacific Biosciences of California, Inc. is empowering life scientists with highly accurate sequencing platforms. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Contacts
Investors:
Todd Friedman
650.521.8450
ir@pacificbiosciences.com
Media:
Kathy Lynch
pr@pacificbiosciences.com
FAQ
What stock options were granted by PacBio on January 14, 2022?
What is the exercise price for the stock options granted by PacBio?
How does the 2020 Inducement Equity Incentive Plan benefit new employees?
What is the vesting schedule for the stock options and RSUs granted by PacBio?